Summit Therapeutics

Summit is a UK company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. Our strategy focuses on two therapy areas: Duchenne Muscular Dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria C. difficile.
Type
Public
HQ
Milton, GB
Founded
2003
Employees
23 (est)

Summit Therapeutics Locations

Milton, GB
Cambridge, US

Summit Therapeutics Metrics

Summit Therapeutics Summary

Founding Date

2003

Market capitalization

£104 M

Closing share price

£1.73

Summit Therapeutics Financials

FY, 2014FY, 2015FY, 2016

Revenue

£1.84 M£2.15 M£1.45 M

Revenue growth, %

16.5%-32.4%

Summit Therapeutics Market Value History

Summit Therapeutics News

Summit Therapeutics Company Life

You may also be interested in